Sentiment-Signal
33,2
Bearisch
Composite Score (0–100)
Insider (25%)
43.3
1 Insider, 4,8M $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
Unternehmen & Branche
| Name | Bicara Therapeutics Inc. |
|---|---|
| Ticker | BCAX |
| CIK | 0002023658 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,17 Mrd. USD |
| Beta | -1,23 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -137,950,000 | -2.52 | 430,994,000 | 401,452,000 | |
| 2025-09-30 | 10-Q | -36,330,000 | -0.67 | 424,688,000 | 402,780,000 | |
| 2025-06-30 | 10-Q | -27,388,000 | -0.50 | 453,587,000 | 435,196,000 | |
| 2025-03-31 | 10-Q | -36,846,000 | -0.68 | 478,077,000 | 458,957,000 | |
| 2024-12-31 | 10-K | -67,995,000 | -4.05 | 509,996,000 | 491,875,000 | |
| 2024-09-30 | 10-Q | -17,481,000 | -1.60 | 524,173,000 | 509,555,000 | |
| 2024-06-30 | 10-Q | -17,049,000 | -19.01 | -174,776,000 | ||
| 2024-03-31 | 10-Q | -12,508,000 | -18.94 | -160,080,000 | ||
| 2023-12-31 | 10-K | -51,985,000 | -89.61 | 233,982,000 | -148,769,000 | |
| 2023-09-30 | 10-Q | -22,845,000 | -38.23 | -137,111,000 | ||
| 2023-06-30 | 10-Q | -9,288,000 | -114,817,000 | |||
| 2023-03-31 | 10-Q | -7,412,000 | -105,908,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -5,500 | 22.88 | -125,830.10 | -48,7% | |
| 2026-04-21 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9,200 | 23.00 | -211,613.80 | -81,9% | |
| 2026-04-20 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -15,000 | 23.61 | -354,145.50 | -137,1% | |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8,000 | 23.01 | -184,058.40 | -71,3% | |
| 2026-04-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4,500 | 23.01 | -103,532.85 | -40,1% | |
| 2026-03-25 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -5,500 | 18.95 | -104,229.40 | -40,3% | |
| 2026-03-23 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9,200 | 18.52 | -170,348.12 | -65,9% | |
| 2026-03-20 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -1,596 | 18.95 | -30,246.27 | -11,7% | |
| 2026-03-19 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -6,905 | 18.78 | -129,704.90 | -50,2% | |
| 2026-03-18 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -6,499 | 18.84 | -122,414.51 | -47,4% | |
| 2026-03-16 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8,000 | 19.66 | -157,256.80 | -60,9% | |
| 2026-03-16 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4,500 | 19.66 | -88,456.95 | -34,2% | |
| 2026-03-09 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -36,766 | 19.17 | -704,657.16 | -272,8% | |
| 2026-03-06 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -3,817 | 18.75 | -71,571.80 | -27,7% | |
| 2026-03-05 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -1,786 | 18.74 | -33,464.10 | -13,0% | |
| 2026-03-04 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -2,963 | 18.25 | -54,061.71 | -20,9% | |
| 2026-03-04 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -2,631 | 18.73 | -49,288.63 | -19,1% | |
| 2026-03-04 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -16,300 | 18.52 | -301,920.01 | -116,9% | |
| 2026-03-03 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -200 | 18.45 | -3,690.00 | -1,4% | |
| 2026-03-03 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -13,555 | 18.22 | -246,909.75 | -95,6% | |
| 2026-03-03 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -12,892 | 18.16 | -234,158.69 | -90,6% | |
| 2026-03-03 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4,500 | 18.16 | -81,733.95 | -31,6% | |
| 2026-02-26 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% Owner | Open Market Purchase | 300,000 | 16.00 | 4,800,000.00 | +1858,1% | |
| 2026-02-25 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -3,108 | 18.04 | -56,066.77 | -21,7% | |
| 2026-02-25 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -523 | 18.04 | -9,434.66 | -3,7% | |
| 2026-01-22 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -3,828 | 18.10 | -69,295.99 | -26,8% | |
| 2026-01-22 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -1,882 | 18.15 | -34,162.44 | -13,2% | |
| 2026-01-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -149 | 18.02 | -2,684.98 | -1,0% | |
| 2025-12-22 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -9,200 | 18.31 | -168,491.56 | -65,2% | |
| 2025-12-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8,000 | 18.68 | -149,470.40 | -57,9% | |
| 2025-12-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4,500 | 18.68 | -84,077.10 | -32,5% | |
| 2025-11-25 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -4,594 | 18.84 | -86,561.99 | -33,5% | |
| 2025-11-25 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -906 | 18.84 | -17,071.21 | -6,6% | |
| 2025-11-24 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -5,500 | 18.45 | -101,475.00 | -39,3% | |
| 2025-11-24 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -17,795 | 18.55 | -330,093.69 | -127,8% | |
| 2025-11-24 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -41,163 | 18.86 | -776,428.85 | -300,6% | |
| 2025-11-21 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4,500 | 18.05 | -81,211.50 | -31,4% | |
| 2025-11-21 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -605 | 18.15 | -10,980.75 | -4,3% | |
| 2025-11-21 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8,000 | 18.05 | -144,376.00 | -55,9% | |
| 2025-10-16 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -24,103 | 18.83 | -453,760.67 | -175,7% | |
| 2025-10-15 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -13,289 | 18.84 | -250,391.34 | -96,9% | |
| 2025-10-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8,000 | 18.16 | -145,243.20 | -56,2% | |
| 2025-10-15 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -4,500 | 18.16 | -81,699.30 | -31,6% | |
| 2025-10-13 | Mazumdar Claire | Director, Officer, Chief Executive Officer | Open Market Sale | -11,445 | 18.92 | -216,545.12 | -83,8% | |
| 2025-10-09 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -6,415 | 18.23 | -116,931.34 | -45,3% | |
| 2025-10-09 | Raben David | Officer, Chief Medical Officer | Open Market Sale | -22,000 | 18.45 | -405,900.00 | -157,1% | |
| 2025-10-08 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -5,627 | 18.21 | -102,456.42 | -39,7% | |
| 2025-10-07 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -8,000 | 18.06 | -144,472.80 | -55,9% | |
| 2025-10-07 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -2,900 | 18.06 | -52,371.39 | -20,3% | |
| 2025-10-07 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -18,244 | 18.22 | -332,385.61 | -128,7% | |
| 2025-10-06 | Hyep Ivan | Officer, Chief Financial Officer | Open Market Sale | -6,514 | 18.17 | -118,356.12 | -45,8% | |
| 2025-10-06 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -24,000 | 18.06 | -433,332.00 | -167,7% | |
| 2025-10-06 | Cohlhepp Ryan | Director, Officer, President and COO | Open Market Sale | -15,600 | 18.06 | -281,665.80 | -109,0% | |
| 2025-09-29 | Meisner Lara | Officer, Chief Legal Officer | Open Market Sale | -33,807 | 14.75 | -498,653.25 | -193,0% | |
| 2025-09-15 | Meisner Lara | Officer, Chief Legal Officer | Open Market Sale | -15,829 | 11.49 | -181,875.21 | -70,4% | |
| 2025-06-16 | Meisner Lara | Officer, Chief Legal Officer | Open Market Sale | -15,829 | 10.43 | -165,096.47 | -63,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.